Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
23 hedge funds and large institutions have $1.13M invested in Evoke Pharma in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
1,350% more call options, than puts
Call options by funds: $29K | Put options by funds: $2K
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
10% more funds holding
Funds holding: 21 → 23 (+2)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
6.69% less ownership
Funds ownership: 12.96% → 6.27% (-6.7%)
79% less capital invested
Capital invested by funds: $5.46M → $1.13M (-$4.33M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$44.2K |
| 2 |
VF
Virtu Financial
New York
|
+$35.4K |
| 3 |
Jane Street
New York
|
+$14.4K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$5.88K |
| 5 |
BlackRock
New York
|
+$4.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$2.21M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$517K |
| 3 |
Morgan Stanley
New York
|
-$101K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$23.5K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$21K |
EVOK Hedge Fund Activity: Q4 2021 in Review
23 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q4 2021, worth a combined $1.13M — down 79% from $5.46M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EVOK positions and 3 closed out — a net gain of 2 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $44.2K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $2.21M sold.
- 23 institutional investors held Evoke Pharma (EVOK) as of Q4 2021, up from 21 in Q3 2021.
- Funds reported $1.13M of Evoke Pharma stock for Q4 2021, down 79% quarter-over-quarter.
- 5 funds opened new Evoke Pharma positions in Q4 2021 and 3 closed out, a net change of +2 holders.
- The largest Evoke Pharma buyer in Q4 2021 was Renaissance Technologies, an estimated $44.2K added.
- The largest Evoke Pharma seller in Q4 2021 was AIGH Capital Management, an estimated $2.21M sold.
Based on aggregated 13F filings for Q4 2021.